Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"Angiotensin Receptor Blocker"”.
-
Clinical profiles and outcomes of patients receiving acute renal replacement therapy in the cardiac intensive care unit at a South African tertiary centre
… of 58.7% and 60.9% respectively. Baseline use of Angiotensin Converting Enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) was associated with a reduced 30 day mortality, Hazards Ratio (HR) 0.43; 95% Confidence interval (95%CI) 0.20 – 0.93; p = 0.031. In addition, heart failure was …
-
Impact Of Time-Varying And Time-Invariant Measures Of Adherence To Secondary Prevention Therapies Post-Acute Myocardial Infarction: An Application Of Marginal Structural Models (MSMS)
… comprised of 1,091 patients, and cohorts B (β-blocker therapy) and C (angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy) included 1,021 and 1,025 patients, respectively. When accounting only for baseline covariates in a discrete-event time model the …
-
The effects of right ventricular pacing in the heart failure population
… data-linkage study demonstrated that <br/>angiotensin receptor blocker or angiotensin converting enzyme inhibitor use <br/>was associated with improved mortality and less hospitalisation for heart <br/>failure in patients paced for complete heart block, who were likely to be <br/>exposed to …
-
Dapagliflozin Regresses Left Ventricular Hypertrophy in People with Type 2 Diabetes
… for baseline LVM, blood pressure, weight and angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) prescription showed the LVM change to remain statistically significant (mean change -2.87g (95% CI: -5.27 to -0.48, p=0.02)). Dapagliflozin induced LVM regression …
-
Young-Onset Type 2 Diabetes in the Auckland Region - Clinical Outcomes and Healthcare Service Use in Comparison to Type 1 Diabetes
… >30mg/mmol were not dispensed an ACE inhibitor/angiotensin receptor blocker. Conclusions: A comprehensive strategy is needed to better manage young-onset T2D addressing socioeconomic disparities.
-
A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery
… surgery increasing numbers are taking either an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin receptor blocker(ARB). The current recommendations whether to continue or withhold ACE-I and ARB in the perioperative period are conflicting. Previous metaanalyses have linked …
-
Charakterisierung des Angiotensin II AT1-Rezeptors in humanen differenzierten Podozyten
… von allen wesentlichen Bestandteilen des Renin-Angiotensin-Systems in humanen differenzierten Podozyten gezeigt, sondern auch die Funktionalität dieses RAS nachgewiesen. Es wurden hierzu besonders die Eigenschaften des AT1-Rezeptors untersucht. Mittels Messung der [Ca2+]i wurde die …
-
Losartan, an angiotensin II receptor blocker, fails to attenuate pulmonary dysfunction in ovine burn and smoke model
Elevated levels of angiotensin II (AngII) in the lung have been shown in response to burn and smoke inhalation injury. AngII has been associated with increased nitric oxide levels, leading to nuclear oxidative damage in Type II lung epithelial cells. Losartan is an AngII, AT1A specific receptor …
-
Pathophysiological role of aldosterone in cardiac remodelling after myocardial infarction
… and the effects of the mineralocorticoid receptor antagonist eplerenone, in a cohort of 100 patients admitted with AMI, with depressed LV ejection fraction (LVEF) but without HF or diabetes mellitus, using a gold standard modality for LV functional assessment and infarct imaging: late …
-
Relationship Between Angiotensin Receptor Blockers and Cancer: A Nested Retrospective Longitudinal Cohort Study
<p> Angiotensin receptor blockers (ARBs) are commonly prescribed drugs that have proven benefits among patients with cardiovascular and diabetic diseases. Recently a concern of modest increase in the risk of solid cancers among ARB users was reported. This became controversial, as many experts …